- Home
- / GH Research
GH Research
Stock Price
$8.1
2024-10-29
Market Capitalization
$421.4 M
2024-10-29
GH Research Summary
Company Summary
- Overview
- GH Research Ireland is a biopharmaceutical company developing therapies for psychiatric and neurological disorders. It focuses on long-acting therapies and develops GH001 and GH002 products. GH001 is a drug product for 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) for patients with treatment-resistant depression (TRD). GH002 is an injectable formulation of 5-MeO-DMT.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Dublin 2, IE | view all locations
- Website
- https://www.ghres.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Magnus Halle, Co-Founder & Managing Director
Julie Ryan, Group Finance Director
Florian Schönharting, Director
LocationsView all
1 location detected
Dublin 2, D HQ
Ireland
28 Baggot Street Lower
GH Research Financials
Summary Financials
- Net income (FY, 2025)
- ($48.3M)
- Cash (FY, 2025)
- $246.3M
- EBIT (FY, 2025)
- ($60.7M)
- Enterprise value
- $175.7M